SomaLogic, Inc. (SLGC) News
Filter SLGC News Items
SLGC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SLGC News Highlights
- For SLGC, its 30 day story count is now at 12.
- Over the past 16 days, the trend for SLGC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about SLGC are LAB, DEC and GOLD.
Latest SLGC News From Around the Web
Below are the latest news stories about SOMALOGIC INC that investors may wish to consider to help them evaluate SLGC as an investment opportunity.
Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioToolsDr. Larry Gold, the founder of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic's current Chief Technology Officer, are issuing the below letter to SomaLogic's stockholders regarding their opposition to the Company's proposed merger with Standard BioTools, Inc. ("Standard") (Nasdaq: LAB). |
SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading DisclosureSomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today issued the following statement in response to a press release issued by Madryn Asset Management, LP ("Madryn") on December 26, 2023, regarding the pending merger with Standard BioTools (Nasdaq: LAB): |
Madryn Asset Management Releases Evidence That SomaLogic Ran a Flawed and Incomplete Review of AlternativesNEW YORK, December 26, 2023--Madryn Asset Management, LP (collectively with its affiliates, "Madryn" or "we"), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC), today disclosed that the Transaction Committee of the Company’s Board of Directors (the "Transaction Committee") did not pursue a substantive dialogue with Laboratory Corporation of America Holdings ("Labcorp") (NYSE: LH) – one of the industry’s most logical s |
Madryn Asset Management Sends Letter to ISS Respectfully Requesting it Withdraw "Cautionary Support" for SomaLogic’s Value-Destructive Proposed Merger with Standard BioToolsNEW YORK, December 24, 2023--Madryn Asset Management, LP (collectively with its affiliates, "Madryn" or "we"), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC), today issued the following letter to Institutional Shareholder Services, Inc. ("ISS") following ISS’ publication of a report that recommends "cautionary support" for the Company’s proposed merger (the "Proposed Merger") with Standard BioTools Inc. ("Standard B |
Madryn Asset Management Reiterates Alternative Path to SomaLogic’s Value-Destructive Proposed Merger with Standard BioToolsNEW YORK, December 23, 2023--Madryn Asset Management, LP ("Madryn Asset Management" and, collectively with its affiliates, "Madryn" or "we"), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC), today reiterated its view that there is a viable alternative to the proposed merger (the "Proposed Merger") with Standard BioTools Inc. (Nasdaq: LAB). Madryn issued the following statement: |
ISS Recommends SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioToolsCompany Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special MeetingBOULDER, Colo., Dec. 22, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services (“ISS”) has recommended that SomaLogic stockholders vote “FOR” the pending merger with Standard BioTools at the company’s Special Meeting of Stockholders to be held on January 4, 2024. In its “FOR” recommendation to SomaLogic stockholders, ISS n |
Madryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioToolsNEW YORK, December 22, 2023--Madryn Asset Management, LP ("Madryn Asset Management" and, collectively with its affiliates, "Madryn"), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC), today commented on the additional disclosures provided late yesterday afternoon by SomaLogic related to its proposed merger (the "Proposed Merger") with Standard BioTools Inc. ("Standard BioTools") (Nasdaq: LAB). Madryn issued the follow |
SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioToolsCombination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn’s Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a Standalone Strategy and Potential Benefits of the Merger Urges Stockholders to Vote “FOR” Merger Ahead of Special Meeting of Stockholders on January 4, 2024 BOULDER, Colo., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (Nasdaq: SLGC) today issued an open letter to stockholders highl |
Madryn Asset Management Issues Letter to Shareholders Correcting False and Misleading Statements in SomaLogic’s Recent Investor PresentationNEW YORK, December 21, 2023--Madryn Asset Management, LP ("Madryn Asset Management" and, collectively with its affiliates, "Madryn"), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC), today issued a letter to shareholders to point out the numerous false and misleading statements in the investor presentation (the "SomaLogic Investor Presentation") issued on December 19th by the Company in support of its proposed merger |
Skye Fund III Issues Letter Regarding Opposition to SomaLogic’s Proposed Merger with Standard BioToolsBelieves that the Proposed Merger Grossly Undervalues SomaLogic and Ignores its Revolutionary Products, Considerable Cash Position, and Strong Balance Sheet Iterates that SomaLogic can Thrive as a Standalone Enterprise and Does Not Need Standard BioTools to Thrive Expresses Serious Concerns with Other Aspects of the Proposed Merger, including Potential Conflicts of Interest BALTIMORE, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Skye Fund III, which together with its affiliates, owns approximately 3.4 mill |